Drug Search Results
More Filters [+]

Loracarbef

Alternative Names: loracarbef, lorabid
Latest Update: 2021-04-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Chile | Colombia | Germany | Ireland | Italy | New Zealand | Peru | Philippines | South Africa | Sweden | Taiwan | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Loracarbef

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Osteomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRESTO:Osteo

P1

Terminated

Osteomyelitis

2018-11-07

Recent News Events

Date

Type

Title